Pharma: Clinic Roundup
Tuesday, May 29, 2012
Pfizer Inc., of New York, said the European Medicines Agency's Committee for Human Medicinal Products recommended marketing authorization for axitinib as a second-line treatment for adults with advanced renal cell carcinoma.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.